
Krys Receives Positive CHMP Opinion: A Steps Forward in EU Approval Process for Skin Disease Drug
Krystal Biotech’s Vyjuvek Receives Positive CHMP Opinion for Dystrophic Epidermolysis Bullosa Treatment in the EU In a recent development that holds great significance for the medical community and patients suffering from dystrophic epidermolysis bullosa (DEB), the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion…